ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized disease

Urology

Volumn 82, Issue 2, 2013, Pages 394-399

  Teng, Liang Hong ^a   Wang, Cheng ^a   Bégin, Louis R ^b   Dolph, Michael ^a   Yilmaz, Asli ^a   Trpkov, Kiril ^a   Donnelly, Bryan ^a   Bismar, Tarek A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR ERG;

ARTICLE; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; COMPARATIVE STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION;

ADENOCARCINOMA; CHI-SQUARE DISTRIBUTION; EPITHELIAL CELLS; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM GRADING; ORCHIECTOMY; PROSTATIC NEOPLASMS; TISSUE ARRAY ANALYSIS; TRANS-ACTIVATORS;

EID: 84880916233     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2013.03.029     Document Type: Article

References (29)

1. S.A. Tomlins, D.R. Rhodes, and S. Perner Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer Science 310 2005 644 648
2. S.A. Tomlins, R. Mehra, and D.R. Rhodes TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer Cancer Res 66 2006 3396 3400
3. B.E. Helgeson, S.A. Tomlins, and N. Shah Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer Cancer Res 68 2008 73 80
4. K.G. Hermans, H.A. van der Korput, and R. van Marion Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer Cancer Res 68 2008 7541 7549
5. W. Liu, C.M. Ewing, and B.L. Chang Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers Genes Chromosomes Cancer 46 2007 972 980
6. J.M. Mosquera, S. Perner, and E.M. Genega Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications Clin Cancer Res 14 2008 3380 3385
7. T.A. Bismar, M. Dolph, and L.H. Teng ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality Eur J Cancer 48 2012 538 546
8. S. Perner, F. Demichelis, and R. Beroukhim TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer Cancer Res 66 2006 8337 8341
9. F. Demichelis, K. Fall, and S. Perner TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort Oncogene 26 2007 4596 4599
10. O.R. Saramäki, A.E. Harjula, and P.M. Martikainen TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis Clin Cancer Res 14 2008 3395 3400
11. A.D. Darnel, C.J. Lafargue, and R.T. Vollmer TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort Cancer Biol Ther 8 2009 125 130
12. B. Furusato, S.H. Tan, and D. Young ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification Prostate Cancer Prostatic Dis 13 2010 228 237
13. G.J. van Leenders, J.L. Boormans, and C.J. Vissers Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice Mod Pathol 24 2011 1128 1138
14. T.L. Lotan, N.S. Gupta, and W. Wang ERG gene rearrangements are common in prostatic small cell carcinomas Mod Pathol 24 2011 820 828
15. V.J. Scheble, G. Scharf, and M. Braun ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer Virchows Arch 461 2012 157 162
16. S. Perner, J.M. Mosquera, and F. Demichelis TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion Am J Surg Pathol 31 2007 882 888
17. T.A. Bismar, M. Yoshimoto, and R.T. Vollmer PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer BJU Int 107 2011 477 485
18. K. Park, S.A. Tomlins, and K.M. Mudaliar Antibody-based detection of ERG rearrangement-positive prostate cancer Neoplasia 12 2010 590 598
19. T.A. Bismar, M. Yoshimoto, and Q. Duan Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer Histopathology 60 2012 645 652
20. O. Leshem, S. Madar, and I. Kogan-Sakin TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model PLoS One 6 2011 e21650
21. S.M. Falzarano, M. Zhou, and P. Carver ERG gene rearrangement status in prostate cancer detected by immunohistochemistry Virchows Arch 459 2011 441 447
22. A. Chaux, R. Albadine, and A. Toubaji Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas Am J Surg Pathol 35 2011 1014 1020
23. O. Yaskiv, X. Zhang, and K. Simmerman The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies Am J Surg Pathol 35 2011 1062 1068
24. M. Braun, D. Goltz, and Z. Shaikhibrahim ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer - a comparative study of two monoclonal antibodies Prostate Cancer Prostatic Dis 15 2012 165 169
25. S. Perner, M.A. Svensson, and R.R. Hossain ERG rearrangement metastasis patterns in locally advanced prostate cancer Urology 75 2010 762 767
26. B. Han, R. Mehra, and K. Suleman Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma Mod Pathol 22 2009 1176 1185
27. J.M. Mosquera, S. Perner, and F. Demichelis Morphological features of TMPRSS2-ERG gene fusion prostate cancer J Pathol 212 2007 91 101
28. M. Miettinen, Z.F. Wang, and A. Paetau ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma Am J Surg Pathol 35 2011 432 441
29. G. Attard, A.H. Reid, D. Olmos, and J.S. de Bono Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven Cancer Res 69 2009 4937 4940